
Biotechnology • Pharmaceuticals
Cullinan Oncology is a biopharmaceutical company focused on developing targeted therapeutics to create new standards of care for patients, especially in the fields of oncology, immunology, and translational medicine. With a unique approach to research and development, they identify high-impact targets and pursue the best modality to maintain a deep and diverse pipeline of transformative therapies. Cullinan Oncology emphasizes collaboration both internally and with external academic and industry partners, with the goal of efficiently advancing promising therapies for cancer and autoimmune indications. Their approach is modality-agnostic, aiming to leverage the best scientific collaborations to benefit patients.
11 - 50 employees
Founded 2018
🧬 Biotechnology
💊 Pharmaceuticals
💰 $10M Post-IPO Equity on 2022-03
August 19
Lead data management for assigned programs; oversee vendors. Drive data standards at Cullinan Therapeutics.